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Sustained release (SR) dosage forms enable prolonged and
continuous deposition of the drug in the gastrointestinal
(GI) tract and improve the bioavailability of medications
characterized by a narrow absorption window. In this
study, a new strategy is proposed for the development of
SR dosage forms for theophylline (TPH). Design of the
delivery system was based on a sustained release formu-
lation, with a modified coating technique and swelling
features aimed to extend the release time of the drug. Dif-
ferent polymers, such as Carbopol 71G (CP), sodium car-
boxymethylcellulose (SCMC), ethylcellulose (EC) and their
combinations were tried. Prepared matrix tablets were
coated with a 5 % (m/m) dispersion of Eudragit (EUD)
in order to get the desired sustained release profile over
a period of 24 h. Various formulations were evaluated for
micromeritic properties, drug concentration and in vitro
drug release. It was found that the in vitro drug release
rate decreased with increasing the amount of polymer.
Coating with EUD resulted in a significant lag phase in
the first two hours of dissolution in the acidic pH of simu-
lated gastric fluid (SGF) due to decreased water uptake,
and hence decreased driving force for drug release. Re-
lease became faster in the alkaline pH of simulated intes-
tinal fluid (SIF) owing to increased solubility of both the
coating and matrixing agents. The optimized formula-
tion was subjected to in vivo studies in rabbits and the
pharmacokinetic parameters of developed formulations
were compared with the commercial (Asmanyl®) formu-
lation. Asmanyl® tablets showed faster absorption (tmax
4.0 h) compared to the TPH formulation showing a tmax
value of 8.0 h. The Cmax and AUC values of TPH formu-
lation were significantly (p < 0.05) higher than those for
Asmanyl®, revealing relative bioavailability of about
136.93 %. Our study demonstrated the potential useful-
ness of eudraginated polymers for the oral delivery of the
sparingly soluble drug theophylline.
Keywords: theophylline, polymer blends, modified relea-
se, in vitro release, in vivo release
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When polymers of varying physicochemical properties are blended, they do not in-
teract in the same way with water and drug molecules, resulting in different mobility of
water and drug within the polymeric networks (1–4). Polymer blends sensitive to the
surrounding environment may be of particular interest for many applications (5–7).
The use of Carbopols in drug delivery, especially in sustained release formulations,
may sometimes require other additives because of the high drug release retardant effect
encountered with the polymer (7, 8). These additives are capable of interacting with the
polymer to attenuate release of the incorporated active drug (7, 8). Theophylline, an al-
kaloid found in the leaves of Camellia sinensis is used clinically as a bronchodilator in the
management of chronic obstructive pulmonary disease (9). Theophylline therapy of air-
ways obstruction, associated with asthma and chronic bronchitis, with conventional im-
mediate release regimen tablets or solutions requires treatment every six hours due to
the short half-life of theophylline in the body and its narrow therapeutic index, with
5–20 mg mL–1 serum concentrations (9). Thus, sustained release dosage forms of theo-
phylline can provide desirable serum concentrations for prolonged periods without fre-
quent dosing, thereby providing patient compliance.
In this study, the effect of blending ethyl cellulose (EC) and sodium carboxymethyl-




Theophylline powder (TPH) and ethylcellulose (EC) (Sigma, UK), Eudragit l-100
(Rohm Pharma, Italy), Emcocel® 50 (microcrystalline cellulose, Penwest Pharmaceuti-
cals, England), Carbopol 71G (Noveon, USA), sodium carboxymethyl cellulose (SCMC)
(Wako, Japan) were used. All other chemicals were of analytical grade.
Asmanyl® 300 SR tablet (Square Pharmaceuticals Ltd., Bangladesh) is a sustained
release tablet containing theophylline BP 300 mg in a sustained release formulation.
Animals and in vivo studies on theophylline from optimized tablet matrices
Adult male New Zealand white rabbits weighing 3.75–4.95 kg were used. They were
kept at standard temperature (26 ± 1 °C), 12 h light/dark cycle, fed standard rodent feed
and had free access to drinking water. The animals were fasted for 20 h before experi-
ment. Experiments were started at the same time of the day and fasting was continued
for the first 9 h of the experiment.
Approval was obtained from the institutional ethical board (IEB). Guidelines on the
use of animals were observed in accordance with the »Principles of Laboratory Animal
Care« and institutional standard operating procedures.
Animals were divided into two groups of 5 animals each. Group one administered
one tablet F15 each, while group two received one Asmanyl® tablet each. Blood samples
were collected after 30 min via the ear artery, centrifuged, and the plasma drug concen-
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tration was determined spectrophotometrically at 277 nm using a Shimadzu UV 160 A
spectrophotometer (Shimadzu, Japan) (10). This was repeated at different time intervals
over a period of 24 h.
Pharmacokinetic analysis
Pharmacokinetic analysis was performed using a bioavailability Calc 2002 pharma-
cokinetic analysis computer program (Korea Food & Drug Administration, Korea). Area
under the curve (AUC) was calculated using the linear trapezoidal rule. Maximum plas-
ma concentration (Cmax) and the time needed to reach the maximum plasma concentra-
tion (tmax) were determined directly from the concentration-time data. The elimination
rate constant (Kel) was obtained from the terminal slope using regression analysis, and
the half-life (t1/2) of the drug was calculated by a relationship of 0.693/Kel. Relative bio-
availability was calculated as percentage of the AUC of TPH formulations to Asmanyl®
tablets.
Preparation of theophylline granules and compressed matrices
Wet granulated tablet formulation containing 33.3 % theophylline, 10, 20 and 30 %
(m/m) of the various polymers and their binary blends in ratios of 1:1, 3:1, and 1:3, 1 %
magnesium stearate and Emcocel were prepared. The composition of different matrix
tablets is given in Table I. The drug and each polymer were dispersed in 5 mL of hot wa-
ter at  100 °C. Dispersed polymer and drug were mixed thoroughly and then the re-
quired amount of diluent was added and thoroughly kneaded. The semi-liquid mix was
extruded onto glass slides and dried in a hot air oven at 60 °C for 24 h. Dried rods were
pulverized using a blender for 10 min passed through a sieve (250 mm) and finally com-
pressed into compacts at 27.5 kN, on a single punch tablet press (THP Shanghai, Tian-
xiang ad Chentai Pharmaceutical Machinery, China) equipped with a 10.5-mm punch
and die set. The prepared tablets were soaked in 5 mL (5 %, m/m) aqueous dispersion of
Eudragit l–100 for 24 h. Swollen tablets were again dried at 60 °C for 24 h. A total of
eighteen batches of the matrix tablets with almost constant theoretical mass of 300 mg
were produced. Fifty tablets were made for each batch.
The bulk, tapped density, compressibility and angle of repose were determined us-
ing standard methods (11). Triplicate determinations for each parameter are reported.
In vitro drug release
Drug release study was carried out at 37 ± 0.5 °C using the USP (12) basket type dis-
solution test apparatus. The basket apparatus was used in order to reduce variability
due to the hydrodynamic conditions of the test and to overcome the problem of possible
sticking of the gelled matrix on the wall of the dissolution vessel. The study was per-
formed using an Erweka DT 8 liter dissolutions rate tester (Erweka, Germany) at a
speed of 100 rpm. A 900-mL volume of dissolution medium was used at varying pH to
simulate the gastrointestinal pH variation; the simulation of gastrointestinal transit con-
ditions was achieved by altering the pH of the dissolution medium at various time inter-
vals. The pH of the dissolution medium was kept at 1.2 for 2 h with 0.1 mol L–1 HCl.
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Then, 0.01 mol L–1 of KH2PO4 and 0.02 mol L–1 g of Na2HPO4 ´ 2H2O were added, ad-
justing the pH to 6.8 by adding 1.0 mol L–1 NaOH. A release rate study was continued
for another 3 h. At preset time intervals, 5-mL aliquots were withdrawn using a pipette
fitted with a micro filter and replaced immediately with an equal volume of fresh disso-
lution medium. The samples were analyzed spectrophotometrically at 272 nm using.
The data presented are averages of triplicate determinations.
RESULTS AND DISCUSSION
Micromeritic properties of granules
The granules micromeritic properties are shown in Table II. Angle of repose ranged
from 22.32 to 32.07° indicating that all the granules had a reasonable flow potential. Ac-
cording to Staniforth (13), angles close to 25° correspond to very good flow properties.
Our results show that, apart from batches F2 (containing Carbopol alone), F6 (containing
EC alone) and F16 (containing a blend of Carbopol and SCMC 3:1), all other batches
showed very good flow. The binary combination of EC and Carbopol was observed to
74
M. Emeje et al.: Eudraginated polymer blends: A potential oral controlled drug delivery system for theophylline, Acta Pharm. 62
(2012) 71–82.









F1 100 30 0 0 167 3.0
F2 100 60 0 0 137 3.0
F3 100 90 0 0 107 3.0
F4 100 0 30 0 167 3.0
F5 100 0 60 0 137 3.0
F6 100 0 90 0 107 3.0
F7 100 90 30 0 77 3.0
F8 100 60 60 0 77 3.0
F9 100 30 90 0 77 3.0
F10 100 0 0 30 167 3.0
F11 100 0 0 60 137 3.0
F12 100 0 0 90 107 3.0
F13 100 0 90 30 77 3.0
F14 100 0 60 60 77 3.0
F15 100 0 30 90 77 3.0
F16 100 90 0 30 77 3.0
F17 100 60 0 60 77 3.0
F18 100 30 0 90 77 3.0
C71 – Carbopol; EC – ethylcellulose; SCMC – sodium carboxymethylcellulose
improve the flow (F7 and F8). This may be attributed to the hydrophobic nature of EC
which may adsorb water molecules usually associated with Carbopol formulations.
Compressibility index (CI) is an indicator of changes that occur in the packing ar-
rangement powder tapping, and is a direct measure of the propensity of a powder to
consolidate while undergoing vibration, shipping and handling (13) Table II shows that
the compressibility index was highest for batch F3 (containing 30 % Carbopol) which
expectedly had a low flow rate. However, blending Carbopol with EC (F7–F9) or SCMC
(F16–F18) significantly (p < 0.05) reduced the CI values, implying that these polymer ad-
ditives improved the flowability of Carbopol polymer. CI for the granules generally
ranged from 11.6 to 24.6 %. This result shows that the incorporation of EC or SCMC into
Carbopol matrices (F7–F9 and F16–F18) improved the flowability of the single polymer
(F3). It has been reported (13) that powders with CI between 5 and 18 % have satisfac-
tory flowability. Results of the flow rate (FR) show that blending improves the flow of
granules, as indicated by the FR values of batches F13, F17 and F18 compared to the
batches containing single polymers (F1–F6 and F10–F12). The highest value for FR was
obtained for batch F13 containing 30 % EC, the hydrophobic component of that formula-
tion. The high amount of EC in this formulation may have discouraged the take-up of
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a Mean ± SD (standard deviation).
b n = 5
c n = 3
moisture, thereby improving the flow. Flow rate rather than CI is a direct measure of
powder flowability. Blending was generally, found to improve the micromeritic proper-
ties of the formulations.
The results for bulk and tapped densities ranged from 0.526 to 0.663 g mL–1 and
0.667 to 0.811 g mL–1, respectively. Bulk density depends primarily on the particle-size
distribution, particle shape and the tendency of particles to adhere to one another (12).
Tablet properties
Drug content uniformity of the formulations ranged from 98.9 to 100.3 %, signifying
that the tablets possessed satisfactory drug concentration uniformity of the different
batches of tablets. The results of evaluation tests performed on the theophylline matrix
tablets are tabulated in Table III. Mass uniformity of the tablets ranged from 300.0 ± 1.3
mg to 302.0 ± 0.9 mg.
Results in Figs. 1a-c show the release pattern of theophylline from different batches
of formulated matrix tablets containing Carbopol, ethylcellulose and sodium carboxy-
methyl cellulose, respectively. It is obvious that by increasing the concentration of the
polymer from 10 to 30 % (m/m) the release became slower. The extent of drug release re-
tardation as measured by the time required for 50 and 70 % of the drug to be released
(t50 and t70, respectively) was observed to be dependent on both the type and concentra-
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tion of the polymer, with Carbopol exhibiting the greatest retardation effect (Table III), fol-
lowed by EC and SCMC. Although the initial drug release from EC matrices (Fig. 2) was
faster than the release from SCMC matrices (Fig. 3), the overall effect of retardation was
greater in the former (Table III). This phenomenon, which was similarly reported in a
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Fig. 1. In vitro release profile of theophylline from: a) Carbopol tablet matrices, b) ethylcellulose
tablet matrices, c) sodium carboxymethylcellulose tablet matrices, d) Eudragit-coated tablet matri-
ces containing binary mixtures of Carbopol and ethylcellulose at different ratios, e) Eudragit-coated
tablet matrices containing binary mixtures of sodium carboxymethylcellulose and ethylcellulose at
different ratios, f) Eudragit-coated tablet matrices containing binary mixtures of sodium carboxy-
methylcellulose and Carbopol at different ratios. Points represents mean ± SD (n = 3).
previous study (14), is thought to be due to the fact that ethylcellulose, a water-insoluble
polymer, when in contact with water, swells and retards drug release. It displays initial
surface erosion, which is responsible for the initial fast release. The release rate then de-
creases because the external layers of the tablet become depleted and water must pene-
trate deeper layers of the tablet to reach the undissolved drug. This is probably responsi-
ble for a more extended t70 in tablets containing EC (Table III). The concentration depen-
dent decrease in drug release has been attributed to the differences in gel barrier genera-
tion speed as the tablets matrices contact with the dissolution medium. Increasing the
polymer concentration leads to a gel viscosity increase and the active diffusion decrease,
with dissolution speed decreasing (14). These tablet formulations, unlike the usual sus-
tained release tablets with initial burst release during the first hour attributed to surface
erosion of the matrix tablet prior to gel layer formation around the tablet core, did not
exhibit this phenomenon. This is probably due to the acid-resistant coat provided by
EUD. In acidic medium of the SGF, EUD is insoluble, thereby preventing any apprecia-
ble dissolution of matrix tablets. In the simulated intestinal fluid (pH of 6.8), a rapid lib-
eration of the drug was observed (Figs. 1a-f) in all the batches. This could be due to the
fact that, at that alkaline pH an the EUD coat becoming soluble, the polymer complex
might have become permeable and swellable (14). There was, however, a significant dif-
ference in the amount of drug released from the formulations containing single poly-
mers and those containing blends. Fig. 1d illustrates that the blend of Carbopol and EC
showed the lowest extent of drug release, followed by formulations containing carbopol
alone. An explanation for this would be that in tablets containing a blend of Carbopol
and EC, the drug became coated by an insoluble polymer complex, whereas in single
polymer formulations, the drug which is embedded in the polymer matrix is exposed to
the medium (14). The excessive viscosity and thickening property of Carbopol has also
been implicated in its extensive retardant behavior (13). The significant decrease in drug
release of batch F8 (containing 50 % EC and 50 % Carbopol) and F9 (containing 75 % EC
and 25 % Carbopol) compared to batch F7 (containing 25 % EC and 75 % Carbopol) may
be attributed to higher content of the hydrophobic component (EC) in batches F8 and F9.
Similar behavior was noticed in formulations containing EC and SCMC (F13-F15) and
Carbopol blended with SCMC (F16-F18).
In order to define the model that will represent the best fit for the formulations, dis-
solution data was analyzed using Peppas and Korsmeyer equation (15) given by:
Mt/Md = ktn (1)
where Mt is the amount of drug released at time t, and Md is the amount released at time
t = , k is the kinetic constant, and n is the diffusion exponent. The value of exponent n
was used to characterize the mechanism for both solvent penetration and drug release.
The release exponent value is presented in Table III. It was found that neither polymer
blending nor soaking in EUD dispersions altered the release mechanism from the tab-
lets. However, linearity of the percentage the drug released vs. time plots (Figs. 1a-f) of
all the tablet batches indicates that the drug release from the formulations did not follow
a particular release mechanism. For example, the n value for the formulation containing
blends of Carbopol and SCMC (1:1) is 0.78, indicating an anomalous release mechanism,
while all other formulations have the n value lower than 0.5, indicating Fickian release
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mechanism. Although diffusion predominates, solubility characteristics of the polymers
and the drug as well as polymer erosion might have contributed to controlling the drug
release profiles. This behavior commonly occurs in the matrix type pharmaceutical dos-
age forms where more than one transport mechanism is involved, such as erosion and
swelling (14). On the basis of average or optimal values of t50 and t70, batch F15 (contain-
ing a blend of EC and SCMC at a ratio of 1:3) was considered to have performed better
than single polymers. This batch was therefore chosen for in vivo studies in order to pre-
dict its plasma concentration-time profile in rabbits.
Bioavailability in rabbits
Results in Fig. 2 show that the mean plasma concentration of theophylline follow-
ing oral administration to rabbits was higher for the formulated products than for the
commercial tablets. Pharmacokinetic parameters for theophylline, such as the maximum
plasma concentration, peak time and the area under the concentration-time curve, are
listed in Table IV. The tmax of theophylline for the commercial tablets was 4.0 h, which
was faster than for the formulated tablets. The AUC of the formulated products, unlike
Cmax, was significantly (p < 0.05) higher than those of the commercial tablets. The rela-
tive bioavailability of theophylline in the formulated tablets was about 36 % higher than
for the commercial tablets, indicating the feasibility of further development of an effi-
cient oral delivery system. The plasma theophylline level peaked 8 h after oral adminis-
tration of the formulation, and then slowly declined up to 24 h. The AUC (0–24 h) and
AUC (0–) were 405 and 415 µg mL–1 h–1, respectively, and were found to be signifi-
cantly (p < 0.05) higher than the corresponding values (296.10 and 297.10 µg mL–1 h–1,
respectively) for the commercial product. Although it has been suggested that dissolu-
tion of tablets is almost always the rate-limiting step for intestinal absorption (16), this
holds for well water soluble and permeable drugs. Dissolution of the drug from tablets
controls the pharmacokinetics in case of drugs that fall under the biopharmaceutic clas-
sification system (BCS) 1 and 2; BCS 4 drugs possibly depend on dissolution and/or per-
meability constants. The slower dissolution conferred on the tablets by both the nature
of the polymers and technology of formulation may have contributed to the extended
AUC for TPH formulations. Although the formulated products had a significantly (p < 0.05)
extended/improved AUC and tmax values, the Cmax value (23.80 ± 0.33 mg mL–1) was not
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Table IV. Pharmacokinetic parameters of theophylline after oral administration of formulated and
commercial sustained release tablets to rabbits
Pharmacokinetic parameters Formulated SR theophylline tablet (F15) Asmanyl®
Cmax (mg mL–1) 23.80 ± 0.3 24.40 ± 0.3
tmax (h) 8.00 ± 3.4 4.0 ± 1.7
t1/2 (h) 56.80 ± 5.7 5.97 ± 2.2
0–24 AUC (mg mL–1 h–1) 405.45 ± 20.9 296.10 ± 18.8
0– AUC (mg mL–1 h–1) 415.05 ± 34.9 297.10 ± 28.9
Relative bioavailability (%) 136.9 % 100 %
significantly different from that of the commercial product (24.40 ± 0.34 mg mL–1). Poly-
mer swelling and subsequent retardation of drug release from matrix tablets in the for-
mulated products may also be implicated in extended oral bioavailability.
CONCLUSIONS
We have developed a tablet matrix system containing theophylline by using single
and blends of hydrophobic and hydrophilic polymers and a modified coating technique
using a minimal volume of Eudragit dispersion. The prepared theophylline tablets
showed an increase in oral bioavailability of 36 % compared to the commercial product.
This study illustrates the potential usefulness of these polymers and the technology of
preparation for sustained release of theophylline.
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S A @ E T A K
Polimerne mje{avine oblo`ene Eudragitom: Potencijalni sustav
za kontroliranu peroralnu isporuku teofilina
MARTINS EMEJE, LUCY JOHN-AFRICA, YETUNDE ISIMI, OLOBAYO KUNLE i SABINUS OFOEFULE
Pripravci za produljeno osloba|anje (SR) omogu}avaju produljeno i kontinuirano
osloba|anje lijeka u gastrointestinalnom (GI) traktu i pobolj{avaju bioraspolo`ivost lije-
kova s uskim apsorpcijskim prozorom. U radu se predla`e nova strategija za razvoj for-
mulacija s produljenim osloba|anjem teofilina (TPH), koja se temelji na sustavu za pro-
duljeno osloba|anje, kojem je u svrhu produljenja vremena osloba|anja modificiran na-
~in oblaganja i bubrenja. Kori{teni su razli~iti polimeri, kao {to su Carbopol 71G (CP),
natrijeva karboksimetilceluloza (SCMC), etilceluloza (EC) i njihove kombinacije. Priprav-
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ljene matriks tablete oblo`ene su 5-postotnom (m/m) disperzijom Eudragita (EUD) kako
bi se postiglo produljeno osloba|anje tijekom 24 h. U pripravljenim formulacijama odre-
|ena je koncentracija lijeka i in vitro osloba|anje. Rezultati pokazuju da se pove}anjem
udjela polimera smanjuje brzina osloba|anja in vitro. Oblaganje s EUD zna~ajno je pro-
duljilo lag fazu tijekom prva 2 sata otapanja u kiselom pH simuliranog `elu~anog soka
(SGF). Naime, oblaganje usporava ulazak vode i tako smanjuje pogonsku silu za oslo-
ba|anje lijeka. Zbog pove}ane topljivosti oblo`nog sloja i matriksa u lu`natom mediju,
osloba|anje u simuliranoj intestinalnoj teku}ini (SIF) je br`e. Optimizirana formulacija
ispitana je in vivo na ze~evima. Farmakokineti~ki parametri novih formulacija uspore|i-
vani su s komercijalnim pripravkom Asmanyl®. Asmanyl® tablete pokazuju br`u apsor-
pciju (tmax 4,0 h) u odnosu na TPH formulaciju (tmax 8,0 h). cmax i AUC vrijednosti TPH
formulacije bile su zna~ajno (p < 0,05) vi{e od onih za Asmanyl®, {to ukazuje na relativ-
nu bioraspolo`ivost od oko 136,93 %. Stoga smatramo da su polimeri oblo`eni eudra-
gitom potencijalno korisni za oralnu upotrebu te{ko topljivog lijeka teofilina.
Klju~ne rije~i: teofilin, polimerne mje{avine, modificirano osloba|anje, in vitro osloba|anje, in vivo
osloba|anje
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